Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BAFIERTAM vs CALCIUM DISODIUM VERSENATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BAFIERTAM (monomethyl fumarate) is a prodrug that is rapidly hydrolyzed to monomethyl fumarate, which activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to upregulation of antioxidant response elements and cytoprotective proteins. It also modulates immune responses by shifting from a pro-inflammatory to an anti-inflammatory state.
Calcium disodium edetate chelates heavy metals (e.g., lead, cadmium) forming stable, water-soluble complexes that are excreted renally, reducing metal burden and toxicity.
FDA-approved: Treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.,Off-label: None widely documented.
Treatment of lead poisoning (including symptomatic and asymptomatic patients with blood lead levels ≥45 μg/d L in children and ≥70 μg/d L in adults),Off-label: treatment of other heavy metal toxicities (e.g., cadmium, chromium, manganese, nickel)
120 mg orally once daily.
1-2 g intramuscularly or intravenously every 12 hours for 3-5 days, followed by 2-5 days off, repeating as needed.
Approximately 12 hours (range 8–15 hours); permits twice-daily dosing in multiple sclerosis.
Terminal elimination half-life: 20-30 minutes for unchelated drug; lead-chelate complex half-life: 1-2 hours. Clinical context: Short half-life necessitates continuous or repeated dosing for sustained chelation.
BAFIERTAM is a prodrug that is rapidly metabolized by esterases in the gastrointestinal tract, blood, and tissues to monomethyl fumarate. Monomethyl fumarate is further metabolized via the tricarboxylic acid (TCA) cycle, with no significant involvement of cytochrome P450 enzymes.
Not metabolized; excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily via renal excretion as unchanged drug (approximately 80% of the dose); minimal biliary/fecal elimination (<5%).
Renal: >95% as chelated lead complex; biliary/fecal: negligible (<5%)
30–40% bound to plasma proteins, primarily albumin.
<5% bound to plasma proteins (albumin)
Approximately 0.5–0.7 L/kg; indicates distribution into total body water with limited tissue binding.
0.2-0.3 L/kg; primarily distributes to extracellular fluid, minimal intracellular penetration
Oral: Approximately 50% (due to first-pass metabolism); administer with food to reduce GI irritation.
IV: 100%; IM: approximately 80-90% (due to local chelation and partial excretion)
No dose adjustment required for GFR ≥30 m L/min. Not recommended for GFR <30 m L/min.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: administer 50% of usual dose; GFR < 10 m L/min: administer 25% of usual dose or consider alternative therapy.
Use with caution in hepatic impairment; reduce dose to 60 mg once daily in Child-Pugh Class B or C.
No specific guidelines available; use with caution and monitor liver function in severe hepatic impairment (Child-Pugh C).
Not established in pediatric patients.
25 mg/kg/dose intramuscularly or intravenously every 12 hours for 3-5 days; maximum 1 g/dose.
No specific dose adjustment; use with caution due to age-related decline in renal function.
Consider renal function; elderly patients often require dose reduction based on creatinine clearance; start at lower end of dosing range and monitor for adverse effects.
No black box warning.
This drug is not indicated for the treatment of iron deficiency anemia or hemochromatosis. Do not use in patients with severe renal impairment. Prolonged or excessive use may lead to toxicities including renal failure, convulsions, and cardiac arrhythmias.
Lymphopenia: May cause reduction in lymphocyte counts; monitor complete blood count before and periodically during treatment.,Hypersensitivity reactions: Anaphylaxis and angioedema may occur; discontinue if severe.,Progressive multifocal leukoencephalopathy (PML): Reported in patients with prolonged lymphopenia; consider holding therapy if lymphocyte counts drop below 0.2 x 10^9/L.,Hepatic injury: Elevations of liver enzymes have been reported; monitor in patients with pre-existing liver disease.,Flushing and gastrointestinal events: Common; may be managed by taking with food or using aspirin.
Renal toxicity: monitor renal function and urine output; avoid excessive doses. Neurotoxicity: can cause tremors, seizures, and encephalopathy, especially with high doses or rapid infusion. Hydration: maintain adequate hydration to promote urinary excretion. Rebound metal mobilization: may transiently increase tissue metal levels. Hypocalcemia: due to calcium displacement; monitor serum calcium. Cardiac effects: risk of arrhythmias, especially with rapid IV administration.
Known hypersensitivity to BAFIERTAM, monomethyl fumarate, or any excipient.,Concomitant use with dimethyl fumarate or other fumaric acid esters.
Absolute: anuria or severe renal failure (creatinine clearance <20 m L/min). Relative: hypersensitivity to edetate salts, pre-existing renal disease, concurrent use with other nephrotoxic drugs.
Administer with food to reduce flushing and gastrointestinal adverse effects. Avoid alcohol consumption during treatment as it may exacerbate flushing. No specific dietary restrictions are required.
Avoid excessive intake of calcium and vitamin D supplements during therapy (may reduce chelation efficacy). Maintain adequate hydration with water. No specific food restrictions, but a balanced diet is recommended to prevent deficiencies of essential minerals (zinc, copper) that may be chelated.
BAFIERTAM (monomethyl fumarate) is contraindicated in pregnancy. Animal studies show malformations at subclinical doses. No human data; avoid in all trimesters due to teratogenic potential.
Limited human data. Animal studies show fetal toxicity at high doses. First trimester: theoretical risk of chelation of essential minerals. Second and third trimesters: risk of fetal zinc/corper deficiency if prolonged use. Avoid unless maternal benefit outweighs risk.
No data on presence in human milk. M/P ratio unknown. Risk of infant exposure cannot be excluded. Discontinue breastfeeding or drug, considering importance to mother.
Excreted into breast milk in low amounts; M/P ratio unknown. Caution due to potential for infant mineral chelation. Use only if clearly needed.
No dose adjustment data; contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately. Pharmacokinetic changes unknown but drug should not be used.
No specific dose adjustment required; however, monitor for hypocalcemia and mineral depletion. Increased risk of renal toxicity in pregnancy; ensure adequate hydration.
BAFIERTAM (monomethyl fumarate) is a prodrug of monomethyl fumarate, indicated for relapsing forms of multiple sclerosis. Administer with food to reduce flushing and gastrointestinal adverse effects. Titrate as per recommended schedule to improve tolerability. Monitor complete blood count, liver function tests, and renal function at baseline and periodically. Flushing may be reduced by taking with food or using non-enteric coated aspirin (325 mg) 30 minutes prior. Avoid concurrent use with dimethyl fumarate or other fumaric acid esters.
Administer deep IM or slow IV infusion (over 2-4 hours) to avoid thrombophlebitis. Monitor urine output and renal function; nephrotoxicity is dose-dependent. Discontinue if oliguria or rising creatinine occurs. For lead encephalopathy, give concurrently with BAL (dimercaprol) to redistribute lead from CNS to blood. Use with caution in patients with pre-existing renal disease, hepatitis, or history of allergic reactions. EDTA can chelate essential metals (zinc, copper) leading to deficiencies during prolonged therapy.
Take BAFIERTAM exactly as prescribed, usually twice daily with food.,Flushing and gastrointestinal upset are common but may decrease over time; taking with food and gradual dose titration helps.,Do not crush, chew, or open capsules; swallow whole.,Report any signs of infection, unusual bruising or bleeding, or severe abdominal pain to your healthcare provider.,Avoid consuming alcohol, as it may increase flushing risk.,If you miss a dose, take it as soon as you remember unless it is near the time of the next dose; do not double up.,Inform all healthcare providers that you are taking BAFIERTAM.
Report any signs of allergic reaction (rash, itching, difficulty breathing) or injection site pain/swelling immediately.,Drink plenty of fluids (unless instructed otherwise) to help flush out lead through urine.,Avoid taking any other medications, supplements, or over-the-counter products without consulting your doctor, as they may affect treatment.,Do not miss scheduled blood and urine tests; they are essential to monitor lead levels and kidney function.,Severe lead poisoning may cause fatigue, headache, abdominal pain; report these symptoms if they worsen.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BAFIERTAM vs CALCIUM DISODIUM VERSENATE, answered by our medical review team.
BAFIERTAM is a Iron Chelating Agent that works by BAFIERTAM (monomethyl fumarate) is a prodrug that is rapidly hydrolyzed to monomethyl fumarate, which activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to upregulation of antioxidant response elements and cytoprotective proteins. It also modulates immune responses by shifting from a pro-inflammatory to an anti-inflammatory state.. CALCIUM DISODIUM VERSENATE is a Chelating Agent that works by Calcium disodium edetate chelates heavy metals (e.g., lead, cadmium) forming stable, water-soluble complexes that are excreted renally, reducing metal burden and toxicity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BAFIERTAM and CALCIUM DISODIUM VERSENATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BAFIERTAM is: 120 mg orally once daily.. The standard adult dose of CALCIUM DISODIUM VERSENATE is: 1-2 g intramuscularly or intravenously every 12 hours for 3-5 days, followed by 2-5 days off, repeating as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BAFIERTAM and CALCIUM DISODIUM VERSENATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BAFIERTAM is classified as Category C. BAFIERTAM (monomethyl fumarate) is contraindicated in pregnancy. Animal studies show malformations at subclinical doses. No human data; avoid in all trimesters due to teratogenic p. CALCIUM DISODIUM VERSENATE is classified as Category C. Limited human data. Animal studies show fetal toxicity at high doses. First trimester: theoretical risk of chelation of essential minerals. Second and third trimesters: risk of fet. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.